Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a promising company in the biotech industry with a strong focus on developing cannabinoid-based formulations for the treatment of diseases such as Alzheimer's. The company has achieved over 70% patient enrollment in their Phase 2 CALMA trial and reported positive interim results for their investigational drug, IGC-AD1, which has shown potential in suppressing key hallmarks of Alzheimer's disease. The company also has a strong pipeline with 5 novel therapeutic drug candidates for Alzheimer's disease, and their CEO recently presented upcoming milestones. With a current attractive valuation and potential for significant upside opportunities, the company has a positive outlook for the future, although risks such as balance sheet and liquidity risks, regulatory approvals and competition should be considered.

Bears say

IGC Pharma is expected to report its fiscal Q3 2026 results in early March, with expected revenue of $0.2 million and EPS of $(0.02). The company also has a recent change in FYE and reported positive interim results for its Phase 2 trial for IGC-AD1 as a treatment for agitation in Alzheimer's patients. Despite a large market potential, the company's minimal revenue and lack of a known cure for Alzheimer's make it a risky investment opportunity.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.